Fortitude Family Office’s Prelude Therapeutics PRLD Stock Holding History

Fortitude Family Office’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.23K	Hold	230	–	–	﹤0.01%	1676
2026 Q1	$787	Buy	+230	New	+$603	﹤0.01%	1574

Other funds holding PRLD

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

SCM

Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Fortitude Family Office's PRLD Position: Q2 2026 in Review

Fortitude Family Office held its Prelude Therapeutics (PRLD) position steady in Q2 2026 at 230 shares worth $1.23K. The position accounts for ﹤0.01% of the portfolio, ranked #1676.

Fortitude Family Office first reported a position in PRLD in Q1 2026 and has held it in 2 quarters since. 6 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

Fortitude Family Office held 230 shares of Prelude Therapeutics worth $1.23K as of Q2 2026.
Fortitude Family Office left its Prelude Therapeutics share count unchanged in Q2 2026.
Prelude Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1676 holding.
Fortitude Family Office first reported a position in Prelude Therapeutics in Q1 2026 and has held it in 2 quarters since.
6 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.